Covid-19 roundup: BioNTech going head-to-head with Moderna as PhIII mRNA launch looms; Trial on Shinzo Abe’s once-favorite antiviral is inconclusive
It’s a race to the Phase III finish line now for the 2 leading mRNA vaccines in the pipeline for Covid-19.
BioNTech chief Ugur Sahin told the Wall Street Journal that his company will start Phase III testing of their vaccine later this month, setting them up to lateral the data to regulators before the end of this year.
That puts them essentially on the exact same schedule as Moderna is dedicated to. The Massachusetts rival to BioNTech also expects to launch Phase III this month. Lots of rumors have circulated about delays and conflict among the scientists advancing the Moderna jab, but the biotech has consistently stuck to its plan to start a late-stage pivotal this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
